AstraZeneca will discontinue a certain bottle dosage of its breast cancer drug Truqap (capiversatib) by the end of the year but allow 340B covered entities to replenish their supply with an equivalent dose in blister pack package form.
Major Drug Company Sues Louisiana Over 340B Contract Pharmacy Law
Drug manufacturer AstraZeneca, one of the first companies to place restrictions on 340B discounts in the contract pharmacy setting, has [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
